09:39 AM EST - Antibe Therapeutics Inc. : Has filed its financial and operating results for the fiscal quarter ended June 30, 2021. Revenue totaled $2.7 million, compared to $1.1 million for the same period in fiscal 2021. For the quarter ended June 30, 2021, net loss amounted to $6.3 million ($0.13 per share), compared to $4.9 million ($0.16 per share) for the same period in fiscal 2021. Antibe Therapeutics Inc.
shares T.ATE are trading unchanged at $1.24.
